A Study of the Management of Patients Taking Novel Oral Antiplatelet or Direct Oral Anticoagulant Medication Undergoing Dental Surgery in a Rural Setting

Dentistry Journal

Steven Johnston¹ 

[1] Balfour Oral Surgery Unit, NHS Orkney, Balfour Hospital, Kirkwall, Orkney KW15 1BH, Scotland, UK; E-Mail

关键词: NOAP;    DOAC;    Target-specific Oral Anticoagulants (TSOAC);    Novel Oral Anticoagulants (NOAC);    prasugrel;    ticagrelor;    dabigatran;    rivaroxaban;    apixaban;   

DOI  :  10.3390/dj3040102

来源: mdpi

【 摘 要 】

Purpose: Novel oral antiplatelet (NOAP) (prasugrel and ticagrelor) and direct oral anticoagulant drugs (DOAC) (dabigatran, rivaroxaban and apixaban) have emerged in the last decade. This study was undertaken to determine current approaches taken to the management of patients taking these agents in dental practice in a remote and rural setting. Methods: A small retrospective study was carried out in a small island population that identified patients taking one of the above drugs. All national health service and private dental records were examined to determine the type of treatment carried out and whether drug therapy, treatment plans or actual treatment were modified as a result of NOAP or DOAC therapy. In addition other outcomes such as referral to another service for advice or treatment and any adverse bleeding events were noted. Results: 156 dental encounters for 95 patients taking one of the drugs were identified. Significant events were identified in sixteen encounters and the management of patients taking each drug type differed significantly between cases but no patients returned with troublesome post-operative bleeding. Conclusions: The approaches taken by dental surgeons in Orkney in the management of the NOAPs and DOACs varied and this is likely to be a reflection of the limited literature available.

【 授权许可】

CC BY   
© 2015 by the authors; licensee MDPI, Basel, Switzerland.